Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Grbesa, Ivana ^a,b   Pajares, María J ^a,c,d   Martínez Terroba, Elena ^a,c   Agorreta, Jackeline ^a,c,d   Mikecin, Ana Matea ^b   Larráyoz, Marta ^a   Idoate, Miguel A ^d,e   Gall Troselj, Koraljka ^b   Pio, Ruben ^a,d,e   Montuenga, Luis M ^a,c,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF NAVARRA   (Spain)

^d IdiSNA Navarra Institute for Health Research   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; HYDROLASE INHIBITOR; SIRTUIN 1; SIRTUIN 2; SMALL INTERFERING RNA; TENOVIN 1; UNCLASSIFIED DRUG; ACETANILIDE DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN P53; TENOVIN-1; THIOUREA;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL LINE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIMARY TUMOR; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SQUAMOUS CELL CARCINOMA; STAINING; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CANCER STAGING; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

ACETANILIDES; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIRTUIN 1; SIRTUIN 2; THIOUREA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928556772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124670     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29. doi: 10. 3322/caac.21208 PMID: 24399786
2. Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 2013; 6: 1399-1416. doi: 10.2147/OTT.S37750 PMID: 24133372
3. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006; 25: 176-185. PMID: 16170353
4. Stünkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007; 2: 1360-1368. PMID: 17806102
5. Zhang T, Rong N, Chen J, Zou C, Jing H, Zhu X, et al. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS One. 2013; 8: e79162. doi: 10.1371/journal.pone.0079162 PMID: 24223900
6. Sun Y, Sun D, Li F, Tian L, Li C, Li L, et al. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer. 2007; 58: 21-29. PMID: 17624472
7. Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ, et al. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract. 2013; 209: 365-370. doi: 10.1016/j.prp.2013.03.011 PMID: 23702379
8. Sun L, Li H, Chen J, Dehennaut V, Zhao Y, Yang Y, et al. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. J Natl Cancer Inst. 2013; 105: 887-898. doi: 10.1093/jnci/djt118 PMID: 23704280
9. Shin DH, Choi Y-J, Park J-W. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cancer Res. 2014; 74: 298-308. doi: 10.1158/0008-5472.CAN-13-2620 PMID: 24240701
10. Li Z, Xie Q, Chen Z, Lu S, Xia W. Regulation of SIRT2 levels for human non-small cell lung cancer therapy. Lung Cancer. 2013; 82: 9-15. doi: 10.1016/j.lungcan.2013.05.013 PMID: 23915912
11. Lima RT, Barron GA, Grabowska JA, Bermano G, Kaur S, Roy N, et al. Cytotoxicity and cell death mechanisms induced by a novel bisnaphthalimidopropyl derivative against the NCI-H460 non-small lung cancer cell line. Anticancer Agents Med Chem. 2013; 13: 414-421. PMID: 23092269
12. Hoffmann G, Breitenbuecher F, Schuler M, Ehrenhofer-Murray AE. A novel SIRT2 inhibitor with p53-dependent pro-apoptotic activity in non-small-cell lung cancer. J Biol Chem. 2013; 289: 5208-5216. doi: 10.1074/jbc.M113.487736 PMID: 24379401
13. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus, and heart. 1st ed. Lyon: IARC Press; 2004.
14. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9: e1001216. doi: 10.1371/journal.pmed.1001216 PMID: 22675273
15. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006; 66: 2116-2128. PMID: 16489012
16. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004; 64: 9027-34. PMID: 15604268
17. Pajares M, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012; 30: 1129-1136. doi: 10.1200/JCO.2011.37.4231 PMID: 22355056
18. Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman J, Sanchez BA, et al. Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol Biol. 2008; 9: 103. doi: 10.1186/1471-2199-9-103 PMID: 19014639
19. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008; 13: 454-463. doi: 10.1016/j.ccr.2008.03.004 PMID: 18455128
20. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science (80-). 2004; 306: 2105-2108. PMID: 15604409
21. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 2009; 9: 123-128. doi: 10.1038/nrc2562 PMID: 19132007
22. Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer. 2011; 2: 648-662. doi: 10.1177/1947601911417862 PMID: 21941620
23. Revollo JR, Li X. The ways and means that fine tune Sirt1 activity. Trends Biochem Sci. 2013; 38: 160-7. doi: 10.1016/j.tibs.2012.12.004 PMID: 23394938
24. Lejeune A, Vanhove M, Lamotte-Brasseur J, Pain RH, Frère JM, Matagne A. Quantitative analysis of the stabilization by substrate of Staphylococcus aureus PC1 beta-lactamase. Chem Biol. 2001; 8: 831-842. PMID: 11514231
25. Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD, Wolberger C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell. 2002; 10: 523-535. PMID: 12408821
26. Herranz D, Maraver A, Cañamero M, Gómez-López G, Inglada-Pérez L, Robledo M, et al. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene. 2013; 32: 4052-4056. doi: 10.1038/onc.2012.407 PMID: 22986535
27. Huffman DM, Grizzle WE, Bamman MM, Kim J, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007; 67: 6612-6618. PMID: 17638871
28. Chen H, Jeng Y, Yuan R, Hsu H, Chen Y. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol. 2012; 19: 2011-2019. doi: 10.1245/s10434-011-2159-4 PMID: 22146883
29. Holloway KR, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M, et al. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol. 2013; 27: 480-490. doi: 10.1210/me.2012-1347 PMID: 23340254
30. Zhao G, Cui J, Zhang J, Qin Q, Chen Q, Yin T, et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther. 2011; 18: 920-928. doi: 10.1038/gt.2011.81 PMID: 21677689
31. Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012; 29: 3240-3249. doi: 10.1007/s12032-012-0260-6 PMID: 22661383
32. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park B-H, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol. 2011; 42: 204-213. doi: 10.1016/j.humpath.2010.05.023 PMID: 21056897
33. Jang KY, Noh SJ, Lehwald N, Tao G-Z, Bellovin DI, Park HS, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012; 7: e45119. PMID: 23024800
34. Tseng R, Lee C, Hsu H, Tzao C, Wang Y. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia. 2009; 11: 763-770. PMID: 19649206
35. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007; 282: 6823-6832. PMID: 17197703
36. Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 2013; 20: 503-514. doi: 10.1038/cdd.2012.147 PMID: 23175188
37. Chen J, Chan AWH, To K-F, Chen W, Zhang Z, Ren J, et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology. 2013; 57: 2287-2298. doi: 10.1002/hep.26278 PMID: 23348706
38. Kim H-S, Vassilopoulos A, Wang R-H, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011; 20: 487-499. doi: 10.1016/j.ccr.2011.09.004 PMID: 22014574
39. Peters C, Rees J, Hardwick R, Hardwick J, Vowler S, Ong C, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010; 139: 1995-2004. doi: 10.1053/j.gastro.2010.05.080 PMID: 20621683
40. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005; 65: 10457-10463. PMID: 16288037
41. Jung-Hynes B, Ahmad N. Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle. 2009; 8: 1478-1483. PMID: 19377286
42. Chen J, Zhang B, Wong N, Lo AWI, To KF, Chan AWH, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011; 71: 4138-4149. doi: 10.1158/0008-5472.CAN-10-4274 PMID: 21527554
43. Hirai S, Endo S, Saito R, Hirose M, Ueno T, Suzuki H, et al. Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation. PLoS One. 2014; 9: e102831. doi: 10.1371/journal.pone.0102831 PMID: 25033286
44. Liu G, Su L, Hao X, Zhong N, Zhong D, Singhal S, et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012; 16: 1618-1628. doi: 10.1111/j.1582-4934.2011.01401.x PMID: 21801305
45. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012; 109: E187-E196. doi: 10.1073/pnas.1105304109 PMID: 22190494
46. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang S-HL, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006; 2: e40. PMID: 16596166
47. Holloway KR, Calhoun TN, Saxena M, Metoyer CF, Kandler EF, Rivera CA, et al. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A. 2010; 107: 9216-9221. doi: 10.1073/pnas.0911325107 PMID: 20439735
48. Simmons GE, Pandey S, Nedeljkovic-Kurepa A, Saxena M, Wang A, Pruitt K. Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells. PloS One. 2014; 9: e98861. doi: 10.1371/journal.pone.0098861 PMID: 24897117
49. Fong Y, Lin Y-C, Wu C-Y, Wang H-MD, Lin L-L, Chou HL, et al. The antiproliferative and apoptotic effects of sirtinol, a sirtuin inhibitor on human lung cancer cells by modulating Akt/β-catenin-Foxo3a axis. ScientificWorldJournal. 2014; 2014: 937051. doi: 10.1155/2014/937051 PMID: 25184156
50. Li L, Wang L, Wang Z, Ho Y, McDonald T, Holyoake T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012; 21: 266-281. doi: 10.1016/j.ccr.2011.12.020 PMID: 22340598